These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33633048)

  • 1. Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.
    Di Filippo C; Caniato F; Cappelli F; Mattesini A; Meucci F; Sori A; Stolcova M; Agostini C; Bernardo P; Di Mario C
    J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):317-319. PubMed ID: 33633048
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.
    Ielasi A; Loffi M; Buono A; De Blasio G; Tespili M
    J Cardiovasc Med (Hagerstown); 2020 Oct; 21(10):825-828. PubMed ID: 32740411
    [No Abstract]   [Full Text] [Related]  

  • 4. de Winter syndrome or inferior STEMI?
    Wang S; Shen L
    BMC Cardiovasc Disord; 2021 Dec; 21(1):614. PubMed ID: 34961517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Grimfjärd P; Lagerqvist B; Erlinge D; Varenhorst C; James S
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):151-157. PubMed ID: 30698669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
    Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
    Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal platelet inhibition with cangrelor in comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention.
    Fiore M; Gerbaud E; Coste P; Cetran L; Marchand H; Seguy B
    Resuscitation; 2018 Sep; 130():e1-e2. PubMed ID: 29969644
    [No Abstract]   [Full Text] [Related]  

  • 10. Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus.
    Sardella G; Mancone M; Stio RE; Cavallo E; Di Roma A; Colantonio R; Calcagno S
    Circulation; 2017 Aug; 136(6):602-604. PubMed ID: 28784829
    [No Abstract]   [Full Text] [Related]  

  • 11. Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
    Alexopoulos D; Pappas C; Sfantou D; Xanthopoulou I; Didagelos M; Kikas P; Ziakas A; Tziakas D; Karvounis H; Iliodromitis E
    J Am Coll Cardiol; 2018 Oct; 72(14):1750-1751. PubMed ID: 30261967
    [No Abstract]   [Full Text] [Related]  

  • 12. A reversible cause of hypoxaemia in a patient with acute right ventricular infarction.
    Makavos G; Cholevas NV; Rallidis LS
    Hellenic J Cardiol; 2019; 60(4):258-260. PubMed ID: 30448622
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
    Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
    Bowman S; Gass J; Weeks P
    Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Aytekin A; Ndrepepa G; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Lahu S; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Valina C; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
    Circulation; 2020 Dec; 142(24):2329-2337. PubMed ID: 33115278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
    Redfors B; Dworeck C; Haraldsson I; Angerås O; Odenstedt J; Ioanes D; Petursson P; Völz S; Albertsson P; Råmunddal T; Persson J; Koul S; Erlinge D; Omerovic E
    Eur Heart J; 2019 Apr; 40(15):1202-1210. PubMed ID: 30851037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
    Parker WA; Bhatt DL; Prats J; Day JRS; Steg PG; Stone GW; Hamm CW; Mahaffey KW; Price MJ; Gibson CM; White HD; Storey RF;
    Thromb Haemost; 2017 Jun; 117(6):1093-1100. PubMed ID: 28382371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
    Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.